HMZ Pharmaceuticals has developed MagnoTherm, a magnetic nanoparticle drug delivery system for treating castration-resistant prostate cancer. MagnoTherm uses magnetic fields to guide and trigger release of the chemotherapeutic Doxorubicin directly at tumor sites, providing a localized treatment option. HMZ hopes to complete preclinical testing of MagnoTherm by 2015 and begin clinical trials in collaboration with BSD Medical Corporation, which is developing a compatible magnetic hyperthermia system. The company's goals are to improve treatment for prostate cancer patients and obtain FDA approval and market share for MagnoTherm.
HMZ Pharmaceuticals was founded to develop MagnoTherm, a thermal magnetic chemotherapeutic using iron oxide nanoparticles to treat castration-resistant prostate cancer. The three founders completed in vitro studies showing biocompatibility and efficacy. Their goals are to complete animal studies in 2015 and apply for FDA approval to enter clinical trials. They aim to provide an improved treatment option with fewer side effects than current therapies like hormone therapy and chemotherapy. Their vision is to establish MagnoTherm as an innovative cancer treatment worldwide to enhance patient quality of life.
Employment Screening Services (ESS) provides drug testing and background screening services to help businesses protect their companies and employees. ESS offers a wide range of drug testing solutions including urine analysis, hair testing, oral fluid testing, and breathalyzer tests. They utilize a large network of collection sites and labs. ESS can help companies establish customized drug testing programs for pre-employment screening, random testing, post-accident testing, DOT screening, and other needs. Their electronic registration system allows for online ordering and scheduling of tests to streamline the process.
The document discusses the issue of drug diversion, which is defined as the diversion of legally prescribed drugs for illegal purposes. It notes that drug diversion costs the US healthcare system an estimated $72.5 billion per year. Veterinary practices are at risk of drug diversion due to their access and storage of controlled and non-controlled substances. Diversion can occur through various means and at different points in the distribution process. The document outlines regulatory requirements and penalties for diversion violations to emphasize the importance of compliance for veterinary practices.
The document discusses Strand Genomics Inc., which offers genomic analysis and clinical interpretation software and services. It focuses on personalized medicine by using its StrandOmics platform to analyze genomic data and determine disease risks for individuals. StrandOmics aims to make genomic testing routine in medical care to help clinicians make more informed decisions. Strand has grown to over 200 scientists and serves over 2,000 labs and 100,000 patients. Its partnership with Health Care Global Enterprises successfully piloted cancer risk assessment and molecular diagnosis for over 50 patients in India.
This document summarizes a presentation on workers' compensation policy issues and solutions related to opioids. It includes discussions from three presenters on topics like the Ohio Bureau of Workers' Compensation pharmacy program, physician dispensing of opioids, and policy reforms. The Ohio BWC program presentation describes the program's formulary changes from 2011-2014 to curb opioid utilization and other drug spending. It also evaluates the program's impact on reducing opioid prescriptions and medical costs. The physician dispensing presentation examines the financial incentives for dispensing and higher claim costs when physicians dispense opioids. It advocates for legislative reforms to curb dispensing to improve outcomes.
Quest Diagnostics is a leading provider of diagnostic testing, information and services. It has received accreditation from several organizations for its facilities and programs. Through its Employer Solutions division, it offers pre-employment drug screening, background checks, employee health programs, and OSHA compliance testing to help employers maintain safety and productivity. These services include drug and health screening, biometric measurements, personalized reports, and aggregated statistics to identify risks and encourage healthy behaviors.
Nommas Life Sciences is developing diagnostic tests using proprietary lambody technology to detect various cancers. Their first product, NCDK, will be a point-of-care ELISA-like kit that can detect multiple cancers from a single patient sample. Nommas aims to raise $750,000 over 2 years to further develop their platform and commercialize NCDK. If successful, NCDK will fulfill an unmet need in cancer diagnostics and help Nommas become a leader in the field of precision oncology diagnostics. However, Nommas faces competition from large companies and must overcome regulatory hurdles to achieve commercial success.
Pain Management Program Mini Disk Customizable Dtccharliedatuna
The document describes a pain management urine drug test monitoring program that provides value to patients, insurance companies, regulatory agencies, and pain management practices. It offers exclusive LC/MS/MS drug testing, free supplies and billing assistance, and is able to provide practices with increased revenue from insurance reimbursements for drug tests performed. The program aims to prevent prescription drug abuse and diversion in medical practices through comprehensive drug testing and monitoring of patients.
HMZ Pharmaceuticals was founded to develop MagnoTherm, a thermal magnetic chemotherapeutic using iron oxide nanoparticles to treat castration-resistant prostate cancer. The three founders completed in vitro studies showing biocompatibility and efficacy. Their goals are to complete animal studies in 2015 and apply for FDA approval to enter clinical trials. They aim to provide an improved treatment option with fewer side effects than current therapies like hormone therapy and chemotherapy. Their vision is to establish MagnoTherm as an innovative cancer treatment worldwide to enhance patient quality of life.
Employment Screening Services (ESS) provides drug testing and background screening services to help businesses protect their companies and employees. ESS offers a wide range of drug testing solutions including urine analysis, hair testing, oral fluid testing, and breathalyzer tests. They utilize a large network of collection sites and labs. ESS can help companies establish customized drug testing programs for pre-employment screening, random testing, post-accident testing, DOT screening, and other needs. Their electronic registration system allows for online ordering and scheduling of tests to streamline the process.
The document discusses the issue of drug diversion, which is defined as the diversion of legally prescribed drugs for illegal purposes. It notes that drug diversion costs the US healthcare system an estimated $72.5 billion per year. Veterinary practices are at risk of drug diversion due to their access and storage of controlled and non-controlled substances. Diversion can occur through various means and at different points in the distribution process. The document outlines regulatory requirements and penalties for diversion violations to emphasize the importance of compliance for veterinary practices.
The document discusses Strand Genomics Inc., which offers genomic analysis and clinical interpretation software and services. It focuses on personalized medicine by using its StrandOmics platform to analyze genomic data and determine disease risks for individuals. StrandOmics aims to make genomic testing routine in medical care to help clinicians make more informed decisions. Strand has grown to over 200 scientists and serves over 2,000 labs and 100,000 patients. Its partnership with Health Care Global Enterprises successfully piloted cancer risk assessment and molecular diagnosis for over 50 patients in India.
This document summarizes a presentation on workers' compensation policy issues and solutions related to opioids. It includes discussions from three presenters on topics like the Ohio Bureau of Workers' Compensation pharmacy program, physician dispensing of opioids, and policy reforms. The Ohio BWC program presentation describes the program's formulary changes from 2011-2014 to curb opioid utilization and other drug spending. It also evaluates the program's impact on reducing opioid prescriptions and medical costs. The physician dispensing presentation examines the financial incentives for dispensing and higher claim costs when physicians dispense opioids. It advocates for legislative reforms to curb dispensing to improve outcomes.
Quest Diagnostics is a leading provider of diagnostic testing, information and services. It has received accreditation from several organizations for its facilities and programs. Through its Employer Solutions division, it offers pre-employment drug screening, background checks, employee health programs, and OSHA compliance testing to help employers maintain safety and productivity. These services include drug and health screening, biometric measurements, personalized reports, and aggregated statistics to identify risks and encourage healthy behaviors.
Nommas Life Sciences is developing diagnostic tests using proprietary lambody technology to detect various cancers. Their first product, NCDK, will be a point-of-care ELISA-like kit that can detect multiple cancers from a single patient sample. Nommas aims to raise $750,000 over 2 years to further develop their platform and commercialize NCDK. If successful, NCDK will fulfill an unmet need in cancer diagnostics and help Nommas become a leader in the field of precision oncology diagnostics. However, Nommas faces competition from large companies and must overcome regulatory hurdles to achieve commercial success.
Pain Management Program Mini Disk Customizable Dtccharliedatuna
The document describes a pain management urine drug test monitoring program that provides value to patients, insurance companies, regulatory agencies, and pain management practices. It offers exclusive LC/MS/MS drug testing, free supplies and billing assistance, and is able to provide practices with increased revenue from insurance reimbursements for drug tests performed. The program aims to prevent prescription drug abuse and diversion in medical practices through comprehensive drug testing and monitoring of patients.
This document discusses ethics in the pharmaceutical industry. It provides examples of unethical behavior by pharmaceutical companies, such as experiments on human subjects without proper consent and misleading drug advertisements. It also outlines ethical behaviors like integrity, transparency, and prioritizing patient care. The core issues discussed are balancing profit motives with medical research and treatment goals. International regulatory bodies aim to promote ethical standards and enforce codes of conduct.
Fulgent Genetics - Biotech - Total return >200%Rogelio Rea
Fulgent Genetics is a genetic testing company with a market capitalization of $60.7 million. It has more than $40 million in cash and insider ownership of approximately 60% by the founder and CEO. The company provides genetic testing and sequencing at low costs using proprietary technology. It focuses on selling to hospitals and medical institutions, with approximately 86% of test billings being paid. The genetic testing market is growing significantly and Fulgent aims to become a leading provider through expanding its test menu, customer base, and global presence while maintaining low costs.
Many leading pharmaceutical companies recognize the need to explore different means and mechanisms to supply physicians and their patients with samples of prescription medications. This is especially true since many physicians have restricted access to the sales reps that traditionally helped order and restock samples as part of their detailing visits.
While some companies have made substantial forays into the world of physician e-sampling, usually as a supplement to traditional sampling, others have done less in this area. This is important when you consider that 30 percent of patients in the United States are more likely to fill a prescription after initially receiving a sample from a physician. This study identifies and documents current practices and trends in physician e-sampling and explores the rationale for different tactical approaches to sampling and what constitutes success in physician e-sampling.
Considering a career as a pharmacist? These professionals provide patients with prescription medications and information for safe use practices, health and wellness screenings, immunizations and general health advice. This guide provides all the necessary information and resources to get started. Find out everything you need to know about this occupation, including qualifications, pay and standard duties.
The Amazonisation of Healthcare - Start with the Customer & Work BackwardsAnup Soans
Whether Amazon succeeds in the healthcare market, or not, remains to be seen but the reason I believe healthcare is about to get ‘Amazonized’ is because of what Chris Holt, Amazon’s leader of Global Healthcare said recently:
“When we think about the healthcare space, our overall philosophy of obsessing around the customer has served us really well. So, we start with the customer and we work backwards.”
Such thinking comes as breath of fresh air – so antithetic it is to the current thinking in healthcare. Incumbents might smirk at it, but customer obsession is the primary reason why Amazon and other tech companies have built giant corporations at an unbelievable pace.
The rules of the digital economy are different from what we are normally used to. That is why a shift in thinking and mindset is key to winning. New ways of doing business come with new rules...
This presentation provides an overview of Scythian Biosciences Inc., a pharmaceutical company developing cannabinoid-based drug therapies for traumatic brain injury (TBI). It discusses the large market opportunity for treating TBI, outlines Scythian's solution to develop drugs that inhibit immune response and inflammation following TBI, and presents the company's preclinical and clinical development timelines and leadership team.
Drug Utilization in a regulated EnviormentAlok Anand
Tracking drugs across the supply chain in a regulated environment. This white paper brief on would be drug utilization approach of Life Science Industry. This white paper is just a step forward to show future life science industry process automation
Amarani Therapeutics is developing a novel drug delivery system to treat atherosclerotic heart disease. They have conducted 12 interviews with physicians and pharmacists to understand the clinical need for alternative treatments to statins. Their drug candidate, D-PDMP, uses a biopolymer encapsulation to inhibit glycosphingolipid synthesis, an alternative mechanism to statins. Preclinical mouse studies show D-PDMP is 10 times more effective than the drug alone and has a different mechanism of action than competitors. Amarani plans to continue validating the clinical need and market opportunity through additional expert interviews to support further development and partnerships.
Medical Affairs Resources, Structures, & Trends Report SummaryBest Practices, LLC
This survey summarizes research on resources, structures, and trends in medical affairs organizations. The survey collected data from 26 medical affairs leaders at 25 pharmaceutical companies. Key findings include that medical affairs groups typically have a centralized structure reporting to executives, focus over a third of their budget on clinical operations, and have experienced few decreases in resources despite some companies citing economic or product reasons. The research was conducted by Best Practices, LLC to benchmark medical affairs organizations.
Unethical Practices in Pharma - Interesting Study from Pakistan Anup Soans
This study clarifies the current pharmaceutical drug promotion and prescribing practices in Pakistan. The majority of prescribers and national pharmaceutical firms and to some extent the multinational pharmaceuticals are involved in unethical practices in drug promotion and prescribing. Alarming policies governing the drug promotion and prescribing are required to be implemented by the concerned regulatory authorities to avoid unnecessary harm to the patient’s life and pocket through the unethical drug promotion. The prescribers should not accept any incentives, gifts of financial value from any pharmaceutical companies in return for an increase in prescribing selected brand. On the other hand, pharmaceutical companies must compete in the market on the basis of the drug quality and do not offer any valuable gift and incentives to the prescribers. The interaction between doctors and phar- maceutical firms should be restricted within acceptable boundaries and the authorities must be prepared to play an active role. Strengthening the regulatory machinery and formulating policies in this regard in neces- sary. It is essential that a health care professional such as a pharmacist can play an important role in this process since he/she is an expert in the pharmaceutical field as well as more aware of the outcomes of unethical drug prescribing practices such as polypharmacy and adverse drug reactions.
This class calendar lesson shows how to adapt different resources from TpT and SMARTBoard lessons to create a good "Morning Calendar" activity for your kindergarten or first grade class.
This document provides information about payout annuities. Payout annuities allow individuals to convert savings into a guaranteed stream of retirement income. There are various types of annuities that offer lifetime payments, joint lifetime payments, or guaranteed payments for a set period. The payments can be customized in terms of amount, frequency, inflation protection, and beneficiary benefits. The document also outlines the tax treatment of annuity payments and death benefits. Payout annuities can provide individuals with secure retirement income and protection against market risks.
PICK A FLAVA EVENTS is hosting various summer events in South Africa featuring their crew of FLAVA DOLLS models. Their events include beach activations, parties, and competitions in Cape Town, Durban, and Plett from their SUMMER SEASON CAMPAIGN. They will also host THE MODEL HOUSE, housing South Africa's top models for the summer in a mansion hosting various exclusive events. PICK A FLAVA EVENTS offers branding and sponsorship opportunities for their events.
Este documento presenta información sobre diferentes métodos para evaluar proyectos de inversión, incluyendo el valor presente neto, la tasa interna de retorno y el período de recuperación. Explica cómo calcular cada método y cuándo es apropiado utilizarlos. También incluye ejemplos numéricos para ilustrar los cálculos.
This document discusses trade barriers and their objectives and types. It notes that trade barriers can be tariff barriers like taxes or duties on imports, or non-tariff barriers like quotas, licenses, and sanctions. The objectives of trade barriers are to protect domestic industries, promote development, maintain a favorable balance of payments, and generate government revenue. The key types of tariff barriers are import duties, export duties, specific duties, and preferential tariffs under single, double, or triple column tariff systems. Non-tariff barriers include quotas, embargoes, licenses, and sanctions.
LOGIMINCO y SPM are mining services companies located in Colombia and Mexico. Their vision is to be the best mining services supplier by collaborating with clients to achieve their goals through quality work. Their mission is to provide high quality, reliable services through experienced, qualified staff. They value positivity, honesty, respect, loyalty, perseverance, and self-improvement. Their services include exploration project management, generation and evaluation, geological mapping, drilling, modeling, and open pit/underground geology. Their goal is to explore and make discoveries for clients like Minera Lince Dorado, GoGold Resources Inc, and Minera Durango Dorado.
Get the right cancer drug, at right TimeSubin Suresh
Mitra Biotech is a Boston and Bengaluru-based startup that is developing personalized cancer therapies. It focuses on testing drugs on recreated tumor microenvironments in the lab before human trials. This approach has higher success rates and lower toxicity than conventional trials. Mitra Biotech has raised over $27 million to develop these personalized therapies and diagnostics. Major challenges include high costs, ensuring data quality, and coordinating information between different treatment centers.
This document discusses ethics in the pharmaceutical industry. It provides examples of unethical behavior by pharmaceutical companies, such as experiments on human subjects without proper consent and misleading drug advertisements. It also outlines ethical behaviors like integrity, transparency, and prioritizing patient care. The core issues discussed are balancing profit motives with medical research and treatment goals. International regulatory bodies aim to promote ethical standards and enforce codes of conduct.
Fulgent Genetics - Biotech - Total return >200%Rogelio Rea
Fulgent Genetics is a genetic testing company with a market capitalization of $60.7 million. It has more than $40 million in cash and insider ownership of approximately 60% by the founder and CEO. The company provides genetic testing and sequencing at low costs using proprietary technology. It focuses on selling to hospitals and medical institutions, with approximately 86% of test billings being paid. The genetic testing market is growing significantly and Fulgent aims to become a leading provider through expanding its test menu, customer base, and global presence while maintaining low costs.
Many leading pharmaceutical companies recognize the need to explore different means and mechanisms to supply physicians and their patients with samples of prescription medications. This is especially true since many physicians have restricted access to the sales reps that traditionally helped order and restock samples as part of their detailing visits.
While some companies have made substantial forays into the world of physician e-sampling, usually as a supplement to traditional sampling, others have done less in this area. This is important when you consider that 30 percent of patients in the United States are more likely to fill a prescription after initially receiving a sample from a physician. This study identifies and documents current practices and trends in physician e-sampling and explores the rationale for different tactical approaches to sampling and what constitutes success in physician e-sampling.
Considering a career as a pharmacist? These professionals provide patients with prescription medications and information for safe use practices, health and wellness screenings, immunizations and general health advice. This guide provides all the necessary information and resources to get started. Find out everything you need to know about this occupation, including qualifications, pay and standard duties.
The Amazonisation of Healthcare - Start with the Customer & Work BackwardsAnup Soans
Whether Amazon succeeds in the healthcare market, or not, remains to be seen but the reason I believe healthcare is about to get ‘Amazonized’ is because of what Chris Holt, Amazon’s leader of Global Healthcare said recently:
“When we think about the healthcare space, our overall philosophy of obsessing around the customer has served us really well. So, we start with the customer and we work backwards.”
Such thinking comes as breath of fresh air – so antithetic it is to the current thinking in healthcare. Incumbents might smirk at it, but customer obsession is the primary reason why Amazon and other tech companies have built giant corporations at an unbelievable pace.
The rules of the digital economy are different from what we are normally used to. That is why a shift in thinking and mindset is key to winning. New ways of doing business come with new rules...
This presentation provides an overview of Scythian Biosciences Inc., a pharmaceutical company developing cannabinoid-based drug therapies for traumatic brain injury (TBI). It discusses the large market opportunity for treating TBI, outlines Scythian's solution to develop drugs that inhibit immune response and inflammation following TBI, and presents the company's preclinical and clinical development timelines and leadership team.
Drug Utilization in a regulated EnviormentAlok Anand
Tracking drugs across the supply chain in a regulated environment. This white paper brief on would be drug utilization approach of Life Science Industry. This white paper is just a step forward to show future life science industry process automation
Amarani Therapeutics is developing a novel drug delivery system to treat atherosclerotic heart disease. They have conducted 12 interviews with physicians and pharmacists to understand the clinical need for alternative treatments to statins. Their drug candidate, D-PDMP, uses a biopolymer encapsulation to inhibit glycosphingolipid synthesis, an alternative mechanism to statins. Preclinical mouse studies show D-PDMP is 10 times more effective than the drug alone and has a different mechanism of action than competitors. Amarani plans to continue validating the clinical need and market opportunity through additional expert interviews to support further development and partnerships.
Medical Affairs Resources, Structures, & Trends Report SummaryBest Practices, LLC
This survey summarizes research on resources, structures, and trends in medical affairs organizations. The survey collected data from 26 medical affairs leaders at 25 pharmaceutical companies. Key findings include that medical affairs groups typically have a centralized structure reporting to executives, focus over a third of their budget on clinical operations, and have experienced few decreases in resources despite some companies citing economic or product reasons. The research was conducted by Best Practices, LLC to benchmark medical affairs organizations.
Unethical Practices in Pharma - Interesting Study from Pakistan Anup Soans
This study clarifies the current pharmaceutical drug promotion and prescribing practices in Pakistan. The majority of prescribers and national pharmaceutical firms and to some extent the multinational pharmaceuticals are involved in unethical practices in drug promotion and prescribing. Alarming policies governing the drug promotion and prescribing are required to be implemented by the concerned regulatory authorities to avoid unnecessary harm to the patient’s life and pocket through the unethical drug promotion. The prescribers should not accept any incentives, gifts of financial value from any pharmaceutical companies in return for an increase in prescribing selected brand. On the other hand, pharmaceutical companies must compete in the market on the basis of the drug quality and do not offer any valuable gift and incentives to the prescribers. The interaction between doctors and phar- maceutical firms should be restricted within acceptable boundaries and the authorities must be prepared to play an active role. Strengthening the regulatory machinery and formulating policies in this regard in neces- sary. It is essential that a health care professional such as a pharmacist can play an important role in this process since he/she is an expert in the pharmaceutical field as well as more aware of the outcomes of unethical drug prescribing practices such as polypharmacy and adverse drug reactions.
This class calendar lesson shows how to adapt different resources from TpT and SMARTBoard lessons to create a good "Morning Calendar" activity for your kindergarten or first grade class.
This document provides information about payout annuities. Payout annuities allow individuals to convert savings into a guaranteed stream of retirement income. There are various types of annuities that offer lifetime payments, joint lifetime payments, or guaranteed payments for a set period. The payments can be customized in terms of amount, frequency, inflation protection, and beneficiary benefits. The document also outlines the tax treatment of annuity payments and death benefits. Payout annuities can provide individuals with secure retirement income and protection against market risks.
PICK A FLAVA EVENTS is hosting various summer events in South Africa featuring their crew of FLAVA DOLLS models. Their events include beach activations, parties, and competitions in Cape Town, Durban, and Plett from their SUMMER SEASON CAMPAIGN. They will also host THE MODEL HOUSE, housing South Africa's top models for the summer in a mansion hosting various exclusive events. PICK A FLAVA EVENTS offers branding and sponsorship opportunities for their events.
Este documento presenta información sobre diferentes métodos para evaluar proyectos de inversión, incluyendo el valor presente neto, la tasa interna de retorno y el período de recuperación. Explica cómo calcular cada método y cuándo es apropiado utilizarlos. También incluye ejemplos numéricos para ilustrar los cálculos.
This document discusses trade barriers and their objectives and types. It notes that trade barriers can be tariff barriers like taxes or duties on imports, or non-tariff barriers like quotas, licenses, and sanctions. The objectives of trade barriers are to protect domestic industries, promote development, maintain a favorable balance of payments, and generate government revenue. The key types of tariff barriers are import duties, export duties, specific duties, and preferential tariffs under single, double, or triple column tariff systems. Non-tariff barriers include quotas, embargoes, licenses, and sanctions.
LOGIMINCO y SPM are mining services companies located in Colombia and Mexico. Their vision is to be the best mining services supplier by collaborating with clients to achieve their goals through quality work. Their mission is to provide high quality, reliable services through experienced, qualified staff. They value positivity, honesty, respect, loyalty, perseverance, and self-improvement. Their services include exploration project management, generation and evaluation, geological mapping, drilling, modeling, and open pit/underground geology. Their goal is to explore and make discoveries for clients like Minera Lince Dorado, GoGold Resources Inc, and Minera Durango Dorado.
Get the right cancer drug, at right TimeSubin Suresh
Mitra Biotech is a Boston and Bengaluru-based startup that is developing personalized cancer therapies. It focuses on testing drugs on recreated tumor microenvironments in the lab before human trials. This approach has higher success rates and lower toxicity than conventional trials. Mitra Biotech has raised over $27 million to develop these personalized therapies and diagnostics. Major challenges include high costs, ensuring data quality, and coordinating information between different treatment centers.
When the author was a young doctor, they were fascinated by research and discovering new drugs, and their goal was to stop cancer. Understanding how cells divide normally and abnormally is key to beating cancer. Cancer is complex with over 100 types and numerous causes. Efforts to develop new drugs have high failure rates. New collaborations across organizations may help cure cancer through a collective effort and looking deeper into cancer's complex pathways. Early cancer detection is important as tumor size and cell number increases exponentially with later detection. Molecular imaging shows promise for improved and earlier tumor detection and characterization to guide more effective, personalized cancer treatment.
J & J Solutions has developed a closed system transfer device for safer handling of chemotherapy drugs. Their device eliminates risks of contamination, standardizes compounding to reduce errors, improves workflow efficiency, and reduces costs. They are seeking funding to complete product development including alpha and beta testing, obtain FDA approval, and launch the product to address a $1 billion market that is growing due to increasing cancer rates.
10 Most Efficient Drug Delivery Solution Providers in 2023V2_compressed.pdfinsightscare
Insights Care’s latest edition, 10 Most Efficient Drug Delivery Solution Providers in 2023, navigates you to the rapidly changing healthcare landscape.
Ourotech is developing a hydrogel that mimics tumor microenvironments to test cancer drug responses in vitro. Their solution involves obtaining patient tumor samples, growing them in a 96-well plate using a proprietary hydrogel, testing drug and combination treatments, calculating human dosages, and treating the patient. They have shown their hydrogel can better predict drug resistance compared to competitors. With $1.5M funding, they plan to complete preclinical trials, generate revenue from pharmaceutical clients, and develop new prototypes.
Welcome to the M Lab™ Collaboration Centers – where customers can use non-GMP lab spaces to operate equipment, evaluate processes and receive real-time technical support without disrupting production.
Plan your visit: www.merckmillipore.com/mlab
גיל פוגוזליץ- GHP investor presentation (eng) 01-0316ZivBenSira
Goldman Hirsh Partners (GHP) is a business group that specializes in developing and commercializing life science technologies, with a focus on personalized medicine. GHP has created a portfolio of 10 technology companies targeting high-growth markets. GHP's strategy is to provide outstanding returns by using its management expertise to commercialize novel innovations. GHP's portfolio companies include TyrNovo, which is developing personalized cancer treatment, and TerraSafe, which protects underground fuel tanks. By the end of 2017, GHP aims to increase the value of its assets to at least $200 million by bringing portfolio companies to capital markets and through licensing agreements.
Biopharma Informatic, Inc. is a site management organization (SMO) that recruits patients and physicians for clinical trials on behalf of pharmaceutical companies and contract research organizations. As an SMO, it facilitates clinical research by finding suitable trial locations and participants. The company aims to establish a nationwide network and expand globally to meet increasing demand from clients in the rapidly growing clinical research industry.
Welcome to the M Lab™ Collaboration Centers – where customers can use non-GMP lab spaces to operate equipment, evaluate processes and receive real-time technical support without disrupting production.
Plan your visit: www.merckmillipore.com/mlab
Ourotech is developing a hydrogel that mimics tumor microenvironments to test cancer drug resistance outside the body. Their solution involves obtaining tumor samples, growing them in a 96-well plate using the proprietary hydrogel, testing drug and combination treatments, and calculating human dosages. This allows personalized cancer treatment by determining the most effective drugs without trial and error. They have proof of concept data showing their hydrogel can better predict drug resistance compared to other methods. With $1.5M funding, they plan to finish preclinical trials, seek FDA clearance, generate revenue from pharmaceutical clients, and further develop the technology.
This Pill Will Help You Feel Better: Final ProjectHans Mundahl
This document summarizes a Junior Urban Adventure presentation about pharmaceuticals, healthcare, and addiction. It discusses perspectives from a drug rehabilitation center called Hello House, the Massachusetts College of Pharmacy and Health Sciences, and the pharmaceutical company Merck. At Hello House, students learned about its 12-step program and saw its high success rates for helping men recover from drug and alcohol addictions. They also visited MCPHS to explore educational opportunities in healthcare fields. At Merck, they gained insight into the drug development process and clinical trials. Overall, the presentation provided students with a better understanding of difficult issues around addiction, healthcare, and the pharmaceutical industry.
This document provides an agenda for a presentation on Janssen (a division of Johnson & Johnson). The agenda includes an introduction to J&J, Janssen's organizational structure and divisional model, their vision, mission, strategy and goals, sustainability approach, an example product (Balversa), work culture, SWOT analysis, and financial statements and ratios. Key points covered are Janssen's focus on access to affordable medicines, developing innovative products, and their Earthwards sustainability program.
The document discusses opportunities and challenges for GSK's marketing strategy due to various political, economic, social and technological factors. It analyzes GSK's strengths like focus on R&D and parent synergy, as well as weaknesses like limited liquidity position. Opportunities discussed are launch of new products and growth in healthcare markets like India. Threats include uncertain R&D outcomes and government regulations. The document also discusses trends reshaping the healthcare industry like empowered patients and use of real-world data. Major changes in digital health are driving new opportunities for pharma companies.
MDxHealth provides molecular diagnostic tests to improve diagnosis and treatment decisions for urological cancers like prostate and bladder cancer. Their lead product is ConfirmMDx, which helps determine if a repeat biopsy is needed after an initial negative biopsy result. They are also launching SelectMDx, a urine-based test to improve patient selection for initial biopsies. Looking forward, they plan to expand their product portfolio and commercial footprint in the US and EU to address unmet needs in urological cancer testing and help reduce unnecessary invasive procedures.
Oncology initiatives in Women’s Healthcare have gained another valuable therapy to improve patient care and outcomes…
Merck & Co.’s ( NYSE: MRK )Keytruda and combination partner therapy Eisai’s ( OTCMKTS: ESALY ) Lenvima will keep their respective marketing and sales units very busy in the upcoming months. Regulatory agencies in the United States, Canada and Australia have concurrently approval to the Keytruda-Lenvima tandem for women with certain advanced endometrial carcinoma. It represents a significant accomplishment by Merck and Eisai and for government regulatory agencies working together to accelerate the process of advancing medicine whether it’s for completely new products or clinically strategic new indications.
Project Orbis: Improve accuracy and accelerate new drug and indication approvals across multiple nation government agencies...
The parallel decisions are the first made through Project Orbis ;a collaborative initiative of the Food And Drug Administration ( FDA ), the Australian Therapeutic Goods Administration ( TGA ) and Health Canada that seeks to reduce new oncology therapy review turnaround between nations. It champions concurrent submissions by drug manufacturers and collaborative assessments by each of the three government regulatory agencies, sponsors and collaborative reviews by all three agencies.
Project Orbis: A winning initiative for patients and clinicians
New drug approvals and the process of approving additional indications is a detail heavy exercise necessary to qualify performance and safety of medications. By improving the processes within nations and cultivating collaboration between them, patients and clinicians benefit from having access to approved therapies sooner. For advanced medication, payers are often reluctant to cover their costs without specific regulatory approval of precise indications. Project Orbis initiatives helps to overcome this hurdle.
Read the article for complete details and contact John Baresky for further information...
This document analyzes biopharmaceutical company Macrogenics and recommends selling its stock. Key points include:
- Macrogenics focuses on developmental oncology which has low success rates and faces competition from biosimilars.
- Its lead drug margetuximab faces uncertainty due to expected biosimilar competition for breast cancer treatments.
- Macrogenics will need to continue dilutive equity offerings to fund clinical programs and manufacturing expansions.
- The company's platforms are speculative without FDA approvals demonstrating safety and efficacy.
- Macrogenics is overvalued and does not align with the investor's value strategy due to binary risks and clinical uncertainty.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education and product differentiation. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
The document summarizes Diagnostic Quality Model Development Group's new 3D modeling capability for medical imaging centers. It provides details on how the technology works, its benefits for radiologists, surgeons, and patients, expected revenue from its use, and testimonials from medical professionals on the advisory board. Imaging centers can partner with DQMDG to set up the 3D modeling program in their facility for around $106,500, which could generate $219,000-$599,000 in additional annual revenue from more scans, new patient referrals, and 3D model fees.
2. HMZ Pharmaceuticals has developed
MagnoTherm, a thermal magnetic
chemotherapeutic, for the treatment of
castration-resistant prostate cancer.
We hope MagnoTherm will become an
effective treatment option for prostate
cancer patients who have developed
resistance to the current drugs on the
market today.
We hope HMZ Pharmaceuticals will be able
to move this product from the laboratory
to market because it possesses numerous
advantages over current treatment options.
Product
Statement
3. The company is still in the early stages of research.
The in vitro studies are completed and animal
modeling is still in early stage.
All general lab work is conducted at rented laboratory
in Cambridge, MA. However, DFCI serves as the
company’s contract research organization because
they have the appropriate equipment for animal
models and MRI testing.
If the animal model research shows promising results,
the members will convert from a member-managed
llc to a manger-managed llc. This is the mode of
action because the members have limited experience
in business, marketing, finance, and law.
Business Concept
4. Magnotherm consists of Doxorubicin loaded
superparamagnetic nanoparticles which are
approximately 25nm in diameter
Superparamagnetic nature allows for enhanced
contrast properties that open potential applications
for magnetic resonance imaging.
They have the feasibility to trigger encapsulated
Doxorubicin release by the application of specific
radiofrequency and amplitude in an alternating
magnetic field and ensures the localized release of
drug at the tumor site.
Thus, using the concept of magneto chemotherapy,
Magno Therm can be used as an multifuntional
nanocarrier for combined therapy and imaging.
The Product
5. Serves as a theranostic agent that can be used for
both diagnosis and the treatment of the disease
Simultaneous diagnosis of tumor during the
treatment helps in reducing systemic toxic reactions
Targeted delivery of the drug also helps in avoiding
adverse side effects which are commonly seen with
other anticancer drugs
PEGylated coating of Magno Therm also makes these
nanoparticles water soluble and also shows better
dispersibility and enhanced long circulation
Features and benefits of
MagnoTherm
6. Primary goal of HMZ pharmaceuticals is to complete preclinical
studies of Magno Therm by the conclusion of 2015
Later we hope to get IND approval and start clinical trails in
collaboration with BSD Medical corporation.
They are developing a 3-D magnetic hyperthermia system which
also has MRI imaging function
This helps in targeted, triggered drug release and also helps in
giving real time imaging through MRI
Long term goals:
To create value for Magno Therm in the pharmaceutical market
with an anticipated share of 3-7 % of prostate cancer market
To improve quality of life of patients suffering from prostate
cancer by providing a safe and effective therapy
Goals and objectives
7. HMZ Pharmaceuticals is a member-managed
limited liability company that was formed in
Boston, Massachusetts at Northeastern
University.
A limited liability structure was the chosen
business structure as a result of numerous
advantages, such as protected assets, pass-
through taxation, and limited compliance
requirements.
Because all members are first time business
starters it is important that personal assets,
such as homes and savings accounts, are
protected in the event of business debts and
liabilities. In addition, this business structure
will ensure that the company will not pay
taxes at the business level, but instead on the
personal level. Since this company is newly
developed, the advantage of avoiding double
taxation is important.
Current Organization Structure
8. Manasa Jillella developed the idea of the magnetic thermal drug delivery system
while working in a nanomedicine laboratory at Northeastern University. She has
been working on iron oxide nanoparticles for triggered drug release for the past
year since developing the idea.. There she gained laboratory experience in the
research and development, but has worked on numerous cancer research based
projects as well.
Heather Goodwin received her Bachelor of Arts in Biology from College in 2011.
She also holds a minor in mathematics and chemistry.. Her experience in cancer
research dates back to 2010, when she began working in the Vidal laboratory at
Dana-Farber Cancer Institute in Boston, Massachusetts. As a student researcher
she studied Epstein-Barr virus associated cancers by examining disruptions in
normal protein interactions.
Shuang Zhang received her Bachelor of Science in Pharmaceutical Preparation
from China Pharmaceutical University. She also holds a minor in Business
Administration from China Pharmaceutical University. She has engaged in
multiple cancer research projects both in China and US. Currently, she works in
Northeastern University's Center for Pharmaceutical Biotechnology and
Nanomedicine. Her specialty is in nanosystems for cancer drug and siRNA
delivery. She has an extensive understanding on anticancer drug market and
marketing strategy.
Meet the Three Members
9. Board of Mangers: Five members with extensive
experience in pharmaceutical regulatory affairs,
research and development, finance, and sales &
marketing. Delegate the daily operations in the
company as outlined in an operating agreement.
Scientific Advisory Board: Eight members with
extensive experience in FDA law and regulations,
pharmacokinetics and dynamics, drug
development, clinical pharmacology, drug
metabolism, and toxicology. Offer expertise to
board of managers.
Employees: Approximately 10 employees with
backgrounds in health, science, and technology.
Meet the Future Team
Members/Owners:
Ms.Goodwin, Ms.Jillella, & Ms. Zhang
Board of Mangers:
responsible for the daily operations and decisions of
MagnoTherm
Employees
Board of Advisors:
Offer expertise pertaining
to a wide variety of
pharmacuetical
disciplines
Individual Equity
Ms. Goodwin 25.3%
Ms. Jillella 25.3%
Ms. Zhang 25.3%
Board of Managers 20%= 4% each
Advisory Board 4%= 0.5% each
Total = 100%
10. 12/17/2015
Market Summary
Global prostate cancer
market was
approximately $3 billion
in 2009.
The sales of prostate
cancer therapeutics
should exceed $8.1
billion, with a CAGR of
9.3%, by the year 2020
Source: Research and Markets. (2011). Global prostate cancer therapeutics market (2010 – 2020) (opportunity analysis, pipeline
assessment & market forecast). Retrieved from<http://www.researchandmarkets.com/reports/1957286/global_prostate_canc
er_therapeutics_market_2010>
• Market Size:
16. 12/17/2015
Resource and Requirements
Lab: A fully-established lab in a biotech incubator
with all lab equipment will be rented.
Animal test facility: All our animal work will be done in
Dana Farber Cancer Institute. No licenses and permit
for animal work will be needed for HMZ
Pharmaceuticals.
Manufacture facility: A contractor manufacturer will
be hired.
17. Exit Strategy
If advised by the financial advisor on the board of
managers, HMZ Pharmaceuticals will attempt to merge
with another company.
Disadvantages: Possible lack of control for existing staff
members and trouble blending the two company’s
cultures.
Advantages: Some members may still receive cash/stock,
resources form both companies, and some company
members may hold their job titles.
The members feel that the therapy will be extremely useful
in treating prostate cancer, if it is able to get to market.
Therefore, the efforts to expand and better the therapy
should not be wasted, but facilitated by other interested
individuals. 12/17/2015
18. BSD Medical Corporation
Serves as a potential corporation
partner.
They are developing a 3-
dimensional magnetic
hyperthermia system, which also
has MRI imaging function.
It could be useful in directing
MagnoTherm to target sites, for
inducing drug release, and for
giving real-time imaging through
MRI.
12/17/2015
20. 12/17/2015
Marketing and Sales
regional sales manager will
accommondate general marketing
guideline to region-specific plan.
internal distribution: technical
background sales representative,
instruct doctors to use the drug.
promotion starts early.
top physicians in clinical trial.
case collection surveys.
technology based marketing:
presentations, conference
sponsorship.
comprehensive customer service.